Vaxxinity (VAXX) Competitors $0.04 +0.00 (+2.33%) As of 08/29/2025 10:07 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock VAXX vs. NBY, TRAW, INAB, KPRX, SNPX, CARM, CERO, DWTX, APRE, and BFRIShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include NovaBay Pharmaceuticals (NBY), Traws Pharma (TRAW), IN8bio (INAB), Kiora Pharmaceuticals (KPRX), Synaptogenix (SNPX), Carisma Therapeutics (CARM), CERo Therapeutics (CERO), Dogwood Therapeutics (DWTX), Aprea Therapeutics (APRE), and Biofrontera (BFRI). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. Its Competitors NovaBay Pharmaceuticals Traws Pharma IN8bio Kiora Pharmaceuticals Synaptogenix Carisma Therapeutics CERo Therapeutics Dogwood Therapeutics Aprea Therapeutics Biofrontera NovaBay Pharmaceuticals (NYSE:NBY) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk. Do insiders & institutionals believe in NBY or VAXX? 23.3% of NovaBay Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.9% of Vaxxinity shares are owned by institutional investors. 0.1% of NovaBay Pharmaceuticals shares are owned by insiders. Comparatively, 64.1% of Vaxxinity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings & valuation, NBY or VAXX? NovaBay Pharmaceuticals has higher revenue and earnings than Vaxxinity. Vaxxinity is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovaBay Pharmaceuticals$9.78M1.06-$9.64M-$53.72-0.03VaxxinityN/AN/A-$56.93M-$0.45-0.10 Do analysts prefer NBY or VAXX? NovaBay Pharmaceuticals currently has a consensus target price of $0.85, indicating a potential downside of 52.25%. Given NovaBay Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe NovaBay Pharmaceuticals is more favorable than Vaxxinity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovaBay Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to NBY or VAXX? In the previous week, NovaBay Pharmaceuticals had 2 more articles in the media than Vaxxinity. MarketBeat recorded 2 mentions for NovaBay Pharmaceuticals and 0 mentions for Vaxxinity. NovaBay Pharmaceuticals' average media sentiment score of 0.80 beat Vaxxinity's score of 0.00 indicating that NovaBay Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment NovaBay Pharmaceuticals Positive Vaxxinity Neutral Is NBY or VAXX more profitable? Vaxxinity has a net margin of 0.00% compared to NovaBay Pharmaceuticals' net margin of -102.72%. Vaxxinity's return on equity of 0.00% beat NovaBay Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NovaBay Pharmaceuticals-102.72% -7,293.78% -158.41% Vaxxinity N/A N/A N/A Which has more volatility & risk, NBY or VAXX? NovaBay Pharmaceuticals has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Vaxxinity has a beta of -24.16, meaning that its stock price is 2,516% less volatile than the S&P 500. SummaryNovaBay Pharmaceuticals beats Vaxxinity on 9 of the 15 factors compared between the two stocks. Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.58M$827.19M$5.69B$9.74BDividend YieldN/A4.84%6.64%4.48%P/E Ratio-0.101.1283.1926.59Price / SalesN/A26.57515.16159.07Price / CashN/A19.5625.6628.92Price / Book0.406.5111.766.08Net Income-$56.93M-$5.07M$3.27B$265.93M7 Day PerformanceN/A1.52%1.13%0.36%1 Month PerformanceN/A6.96%8.30%5.58%1 Year PerformanceN/A19.64%62.26%19.67% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.04+2.3%N/A+4,300.0%$5.58MN/A-0.1090Gap UpNBYNovaBay Pharmaceuticals0.705 of 5 stars$1.74+93.1%$0.85-51.0%+265.7%$10.11M$9.78M-0.0330Gap UpHigh Trading VolumeTRAWTraws Pharma1.6173 of 5 stars$1.40-0.9%N/AN/A$9.99M$230K0.0217INABIN8bio3.6375 of 5 stars$2.19-2.2%$180.00+8,119.2%-86.0%$9.95MN/A-0.2420Positive NewsKPRXKiora Pharmaceuticals3.4476 of 5 stars$2.85+0.2%$10.00+251.5%-24.9%$9.85MN/A-0.9910Positive NewsSNPXSynaptogenixN/A$7.01-8.4%N/A+47.1%$9.74MN/A-0.704CARMCarisma Therapeutics3.042 of 5 stars$0.23-2.5%$1.93+729.7%-79.9%$9.74M$19.63M-0.1520Gap UpCEROCERo Therapeutics3.4159 of 5 stars$7.99+3.0%$45.00+463.6%-97.0%$9.66MN/A0.008Positive NewsDWTXDogwood Therapeutics1.9948 of 5 stars$4.90-3.2%$10.00+104.1%N/A$9.36MN/A-0.265Positive NewsGap UpAPREAprea Therapeutics3.3361 of 5 stars$1.59+0.6%$15.50+874.8%-54.4%$9.36M$1.50M-0.697BFRIBiofrontera2.9983 of 5 stars$0.91+1.2%$2.75+201.9%-18.7%$9.24M$39.19M-0.4070Positive NewsGap Down Related Companies and Tools Related Companies NovaBay Pharmaceuticals Competitors Traws Pharma Competitors IN8bio Competitors Kiora Pharmaceuticals Competitors Synaptogenix Competitors Carisma Therapeutics Competitors CERo Therapeutics Competitors Dogwood Therapeutics Competitors Aprea Therapeutics Competitors Biofrontera Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VAXX) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VAXX Stock Alerts